105 related articles for article (PubMed ID: 27981835)
1. Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation.
Hugenberg V; Wagner S; Kopka K; Schäfers M; Schuit RC; Windhorst AD; Hermann S
J Med Chem; 2017 Jan; 60(1):307-321. PubMed ID: 27981835
[TBL] [Abstract][Full Text] [Related]
2. Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography.
Butsch V; Börgel F; Galla F; Schwegmann K; Hermann S; Schäfers M; Riemann B; Wünsch B; Wagner S
J Med Chem; 2018 May; 61(9):4115-4134. PubMed ID: 29660282
[TBL] [Abstract][Full Text] [Related]
3. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.
Hugenberg V; Riemann B; Hermann S; Schober O; Schäfers M; Szardenings K; Lebedev A; Gangadharmath U; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
J Med Chem; 2013 Sep; 56(17):6858-70. PubMed ID: 23899323
[TBL] [Abstract][Full Text] [Related]
4. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.
Hugenberg V; Breyholz HJ; Riemann B; Hermann S; Schober O; Schäfers M; Gangadharmath U; Mocharla V; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
J Med Chem; 2012 May; 55(10):4714-27. PubMed ID: 22540974
[TBL] [Abstract][Full Text] [Related]
5. Novel Potent Proline-Based Metalloproteinase Inhibitors: Design, (Radio)Synthesis, and First in Vivo Evaluation as Radiotracers for Positron Emission Tomography.
Kalinin DV; Wagner S; Riemann B; Hermann S; Schmidt F; Becker-Pauly C; Rose-John S; Schäfers M; Holl R
J Med Chem; 2016 Oct; 59(20):9541-9559. PubMed ID: 27696839
[TBL] [Abstract][Full Text] [Related]
6. Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging.
Breyholz HJ; Wagner S; Faust A; Riemann B; Höltke C; Hermann S; Schober O; Schäfers M; Kopka K
ChemMedChem; 2010 May; 5(5):777-89. PubMed ID: 20373323
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability.
Hugenberg V; Hermann S; Galla F; Schäfers M; Wünsch B; Kolb HC; Szardenings K; Lebedev A; Walsh JC; Mocharla VP; Gangadharmath UB; Kopka K; Wagner S
Nucl Med Biol; 2016 Jul; 43(7):424-37. PubMed ID: 27179748
[TBL] [Abstract][Full Text] [Related]
8. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.
Breyholz HJ; Schäfers M; Wagner S; Höltke C; Faust A; Rabeneck H; Levkau B; Schober O; Kopka K
J Med Chem; 2005 May; 48(9):3400-9. PubMed ID: 15857146
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the Biodistribution of Radiofluorinated Barbiturate Tracers for Matrix Metalloproteinase Imaging by Introduction of Fluorescent Dyes as Pharmacokinetic Modulators.
Schwegmann K; Hohn M; Hermann S; Schäfers M; Riemann B; Haufe G; Wagner S; Breyholz HJ
Bioconjug Chem; 2020 Apr; 31(4):1117-1132. PubMed ID: 32181649
[TBL] [Abstract][Full Text] [Related]
10. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
[TBL] [Abstract][Full Text] [Related]
11. A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.
Schrigten D; Breyholz HJ; Wagner S; Hermann S; Schober O; Schäfers M; Haufe G; Kopka K
J Med Chem; 2012 Jan; 55(1):223-32. PubMed ID: 22118188
[TBL] [Abstract][Full Text] [Related]
12. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
[TBL] [Abstract][Full Text] [Related]
13. Potent, selective pyrimidinetrione-based inhibitors of MMP-13.
Reiter LA; Freeman-Cook KD; Jones CS; Martinelli GJ; Antipas AS; Berliner MA; Datta K; Downs JT; Eskra JD; Forman MD; Greer EM; Guzman R; Hardink JR; Janat F; Keene NF; Laird ER; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robertson D; Sperger D; Vaughn-Bowser ML; Waller DM; Yocum SA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5822-6. PubMed ID: 16942871
[TBL] [Abstract][Full Text] [Related]
14. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.
Reiter LA; Mitchell PG; Martinelli GJ; Lopresti-Morrow LL; Yocum SA; Eskra JD
Bioorg Med Chem Lett; 2003 Jul; 13(14):2331-6. PubMed ID: 12824028
[TBL] [Abstract][Full Text] [Related]
15. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo.
Schäfers M; Riemann B; Kopka K; Breyholz HJ; Wagner S; Schäfers KP; Law MP; Schober O; Levkau B
Circulation; 2004 Jun; 109(21):2554-9. PubMed ID: 15123523
[TBL] [Abstract][Full Text] [Related]
16. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors.
Grams F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi V; Menta E; Oliva A; Zimmermann G; Gram F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi VMenta E; Oliva A; Zimmermann G
Biol Chem; 2001 Aug; 382(8):1277-85. PubMed ID: 11592410
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
[TBL] [Abstract][Full Text] [Related]
18. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
[TBL] [Abstract][Full Text] [Related]
19. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.
Wada CK
Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
